Filing Flows › Teleflex (TFX) › Q2 2026 › vs Q2 2025
Teleflex (TFX) Q2 2026 vs Q2 2025 (year over year)
Teleflex's revenue rose $128M (+29%) from $443M in Q2 2025 to $570M in Q2 2026. The biggest changes: Interventional +$98.0M (+86%); Vascular +$20.4M (+9%); Surgical +$9.4M (+9%). Gross margin 58.2% against 60.1% (-1.9 pts).
Teleflex, Q2 2026: revenue $570M (+29% year over year), operating margin 12.8%, net earnings $99.7M, operating cash flow $91.9M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Gross margin | 58.2% | 60.1% | -1.9 pts |
| Operating margin | 12.8% | 20.6% | -7.8 pts |
| Net margin | 17.5% | 27.7% | -10.2 pts |
| Free cash flow margin | 13.7% | -14.6% | +28.3 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Vascular | $246M | $226M | $20.4M | +9% |
| Interventional | $212M | $114M | $98.0M | +86% |
| Surgical | $112M | $103M | $9.4M | +9% |
| Revenue | $570M | $443M | $128M | +29% |
| Gross profit | $332M | $266M | $65.9M | +25% |
| Cost of revenue | $239M | $177M | $61.9M | +35% |
| Other income, net | $30.2M | $33.9M | −$3.7M | -11% |
| Operating profit | $72.8M | $91.1M | −$18.3M | -20% |
| Operating expenses | $259M | $175M | $84.2M | +48% |
| Pre-tax earnings | $103M | $125M | −$22.0M | -18% |
| Research & development | $45.1M | $26.5M | $18.6M | +70% |
| SG&A | $214M | $138M | $76.0M | +55% |
| Net earnings | $99.7M | $123M | −$22.9M | -19% |
| Income tax | $3.4M | $2.5M | $886K | +36% |
| Depreciation & amortization | $49.8M | $36.9M | $12.9M | +35% |
| Share-based compensation | $5.4M | $5.7M | −$217K | -4% |
| Working capital & other | $63.1M | $202M | −$139M | -69% |
| Operating cash flow | $91.9M | −$37.0M | $129M | — |
| Free cash flow (OCF − capex) | $77.9M | −$64.8M | $143M | — |
| Capital expenditures | $14.0M | $27.8M | −$13.8M | -49% |
Questions
How much did Teleflex's revenue grow year over year in Q2 2026?
Teleflex's revenue rose $128M (+29%) from $443M in Q2 2025 to $570M in Q2 2026.
What drove Teleflex's revenue change in Q2 2026?
Interventional +$98.0M (+86%); Vascular +$20.4M (+9%); Surgical +$9.4M (+9%).